ImmuCell Corporation
ICCC
$9.92
$0.151.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.34% | 16.49% | 21.75% | 28.29% | 51.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.34% | 16.49% | 21.75% | 28.29% | 51.63% |
| Cost of Revenue | -12.68% | -3.19% | 6.26% | 22.91% | 41.89% |
| Gross Profit | 44.13% | 64.87% | 60.96% | 40.82% | 80.63% |
| SG&A Expenses | 4.77% | 8.18% | 3.90% | 14.10% | 8.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.44% | -4.27% | -0.11% | 12.13% | 23.97% |
| Operating Income | 249.33% | 185.05% | 151.80% | 93.19% | 68.58% |
| Income Before Tax | 52.09% | 161.43% | 143.83% | 93.29% | 62.80% |
| Income Tax Expenses | 17.17% | 175.00% | 170.73% | 144.19% | 120.00% |
| Earnings from Continuing Operations | 51.78% | 160.98% | 143.51% | 93.03% | 62.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.78% | 160.98% | 143.51% | 93.03% | 62.65% |
| EBIT | 249.33% | 185.05% | 151.80% | 93.19% | 68.58% |
| EBITDA | 394.65% | 10,191.97% | 798.67% | 560.00% | 141.81% |
| EPS Basic | 59.52% | 153.32% | 136.16% | 87.42% | 62.31% |
| Normalized Basic EPS | 184.68% | 152.97% | 128.54% | 77.77% | 61.58% |
| EPS Diluted | 59.17% | 150.64% | 134.48% | 85.84% | 61.08% |
| Normalized Diluted EPS | 184.27% | 152.97% | 128.54% | 77.77% | 61.58% |
| Average Basic Shares Outstanding | 10.54% | 14.35% | 13.05% | 9.34% | 5.39% |
| Average Diluted Shares Outstanding | 10.99% | 14.35% | 13.05% | 9.34% | 5.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |